Check for updates

# Associations between Dietary Acid Load and Migraine Headache Severity and Duration among Women: A Cross-Sectional Study

Moein Askarpour<sup>1</sup>, Ali Sheikhi<sup>1</sup>, Faezeh Khorsha<sup>1</sup>, Mansoureh Togha<sup>2,3</sup> and Khadijeh Mirzaei<sup>1\*</sup>

1. Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran

2. Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

3. Headache Department, Iranian Center of Neurological Research, Tehran, Iran

# Abstract

**Background:** Migraine is considered the most common cause of long-term disability in under-50s, which can lead to unbearable pain and neurological dysfunction. Many factors, especially dietary factors, are suggested to trigger migraine headaches. The present study aimed to examine the association between diet-dependent acid load and severity and duration of headaches among migraine patients.

**Methods:** In this cross-sectional study, a sample of 266 women (18-45 years) with history of migraine headaches was enrolled. Dietary data was collected by using a validated Food Frequency Questionnaire (FFQ). Then, diet-dependent acid load indices including Potential Renal Acid Load (PRAL) and Net Endogenous Acid Production (NEAP) were calculated for the participants. For all cases, anthropometric measurements and headache duration were assessed. Headache severity was determined by Visual Analog Scale (VAS) and Migraine Disability Assessment (MIDAS) questionnaires.

**Results:** In this study, individuals with higher PRAL (OR=1.87, 95% CI=1.19-2.96, p=0.007) and NEAP (OR=1.58, 95% CI=1.02-2.44, p=0.03) scores were 87 and 58%, respectively, more likely to have severe headaches. Moreover, our results showed a significant direct correlation between PRAL ( $\beta$ =0.14, 95% CI=0.56-2.94, p=0.04) and NEAP ( $\beta$ =0.18, 95% CI=0.45-3.34, p=0.01) scores and headache duration of participants.

**Conclusion:** The present study showed that higher diet-dependent acid load scores may be associated with higher headache severity and duration in migraine patients.

Keywords: Diet, Headache, Humans, Female Migraine disorders

#### \* Corresponding author

#### Khadijeh Mirzaei, PhD

Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran **Email:** mirzaei kh@tums.ac.ir

Received: Dec 20 2020 Accepted: Feb 25 2021

#### Citation to this article:

Askarpour M, Sheikhi A, Khorsha F, Togha M, Mirzaei Kh. Associations between Dietary Acid Load and Migraine Headache Severity and Duration among Women: A Cross-Sectional Study. *J Iran Med Counc*. 2021;4(2):93-103.

# Introduction

Migraine is a common cerebral disease, characterized by a recurring type of headache, which could last up to 72 hours (1). It is often accompanied by nausea, vomiting, and sensitivity to light and sound. Though the exact underlying biological mechanism of migraine is still unknown, genetic and environmental factors have appeared to play a significant role. Migraine prevalence among adults is reported to be approximately 12%, which is the first common cause of disability in under-50s. It greatly affects the quality of life and is a huge economic burden (2-4). Therefore, finding the best approach to control and manage this disease is critical. Several medications have been introduced to alleviate the symptoms (5), and given that the major side effects may be created by these medications, proper dietary intervention could be a more reasonable approach towards migraine.

The right balance of acidic and basic compounds must be maintained to reach a proper body function (6). Diet and content of certain food components have a clear impact on acid-base balance. Sulfate and phosphorus as dietary factors contribute to acid load, whereas alkali load is associated with dietary intake of bicarbonate (7,8). In general, meat, cheese, and grain products are strongly acidic foods, while fruit, legumes, and vegetables are considered as alkalizing foods. It has been proposed that high dietary acid load may induce a low-grade metabolic acidosis which is related with the development of metabolic changes such as insulin resistance, diabetes, chronic kidney disease, bone disorders, and other complications (9-11); however, some studies have shown no deleterious effect (12-14). It has been suggested that no or average acid load may be the optimal state for humans (15). In recent studies, certain types of foods have been shown to trigger migraine. Processed foods, fast foods, fermented products, old cheese, coffee, chocolate, fish, beans, and citrus are some of the common dietary items, reported to be responsible for initiating migraine headaches (16). These foods are mostly acid-forming and high intake of them might shift the acid-base balance of the body towards more acidic conditions. Moreover, dietary acid load may lead to some conditions such as a rise in the blood pressure that are commonly regarded as precursors of migraine (11,17). Therefore, it could be assumed that the acidic load of the diet may have a role in initiating migraine headache. No study has been conducted till now to investigate the relationship between those two related factors. Therefore, this cross-sectional study was performed to examine the effect of dietary acid load on the intensity and duration of migraine headaches.

# Materials and Methods *Participants*

In this study, 266 pre-menopausal women aged 18-45 with history of episodic migraine headaches were recruited. The participants in the present cross-sectional study were selected from neurology clinics of Khatam Alanbia and Sina hospitals in Tehran, Iran in 2016. The patients were selected based on pre-determined inclusion and exclusion criteria. To be included in the study, women with migraine and the following criteria were the final candidates: (1) a neurologist's diagnosis of migraine according to the criteria of International Classification of Headache Disorders, 3rd edition (ICHD-3); (2) visiting the headache clinics of hospitals for the first time; and (3) the consent to participate in the research. Patients were excluded from the study if they were on specific diets, pregnant or lactating, had a Body Mass Index (BMI) lower than 18.5, or were diagnosed as under-reporters (<800 kcal/day) or overreporters (≥4,200 kcal/day) of energy intake (No: 28). Moreover, subjects were excluded if they experienced migraine headaches along with other chronic diseases such as diabetes, cancer, hepatitis, CVD, etc. due to the side effect of their disease-specific medications on migraine headaches. The study protocol was approved by the local ethics committee of Tehran University of Medical Sciences, and informed written consent was obtained from all participants.

# Assessment of dietary intake and dietary acid load

Usual dietary intake was evaluated by using a 147item semi-quantitative Food Frequency Questionnaire (FFQ) with acceptable reliability and validity (18). Participants were asked by dietitians during a faceto-face interview to report their consumption frequency for each food item over the past year on a daily, weekly, or monthly basis. Household measures were used to change portion sizes to weight in grams. Due to limited data on the nutrient content of some foods and beverages of Iranian Food Composition Table (FCT), the US Department of Agriculture (USDA) FCT was applied to compute nutrient and energy content of dietary intake. Nutrient intakes in micro and macro levels were calculated using Nutritionist IV software (Hearst Corporation, USA) modified for Iranian foods. Data collected from dietary intake was used to compute dietary acid load. The dietary acid load score was determined by 2 measures of PRAL and NEAP. The PRAL score was computed according to some nutrient intakes using the following formula proposed by Remer et al (19): PRAL (mEq/d) =0.4888× protein  $(g/d) + 0.0366 \times P (mg/d) - 0.0205 \times K (mg/d)$  $-0.0125 \times \text{Ca} (mg/d) - 0. (mg/d)$ . The latter one, NEAP score was based on the following algorithm outlined by Frassetto *et al* (20): NEAP (mEq/d) = 54.5×[protein] intake (g/d) /K intake (mEq/d)]-10.2.

# MIDAS and Visual Analog Scale (VAS) questionnaires

In the present study, a professional neurologist diagnosed episodic migraine according to ICHD-3 criteria (21). To evaluate headache-related disability, the Migraine Disability Assessment (MIDAS) questionnaire was applied. Reliability and validity of the MIDAS questionnaire were assessed in Iranian population (22). Participants answered five questions, about the number of days over the past 3 months in which their performance was limited because of migraine. Then, headache sufferers, based on their overall scores, were divided into 4 levels of grade I (0-5, little or no disability), grade II (6-10, mild disability), grade III (11–20, moderate disability), and grade IV (More than 20, severe disability) (23).

Moreover, assessment of headache pain was done by Visual Analog Scale (VAS) questionnaire. The VAS is comprised of a 10 *cm* horizontal line characterized with the word descriptors at the left end (No pain) and at the right end (Severe pain). Migraine patients mark on the line to show their level of pain. Cut-off points of pain score have been proposed in previous studies; the scoring scale ranged from 1 to 10 and pain categories in three groups included mild pain (1-3), moderate pain (4-7), and severe pain (8-10) (24).

### Assessment of other variables

Weight was measured to the nearest 0.1 kg by a digital scale (SECA, Germany), while wearing one layer

of clothing and no shoes. Height was recorded to the nearest 0.5 *cm* by a wall-mounted stadiometer whereas the shoulders were relaxed and shoes were removed. Body Mass Index (BMI) was calculated based on the equation of "weight (*kg*)/height<sup>2</sup> ( $m^2$ )". To acquire demographic characteristics, a questionnaire was given to all participants which contained questions regarding age, family history of migraine, marital status, specific diets, education level, chronic disease background, occupation, and medicine consumption.

A 30-day headache record list was given to all subjects to obtain headache duration, headache attack onset, and headache severity score based on VAS (Scores range from 0 to 10) after each migraine attack. If subjects encountered any problems, there was an experienced neurologist who would give instructions to participants and answer their questions. International Physical Activity Questionnaire (IPAQ) was used to acquire data on Physical Activity (PA), which was shown as metabolic equivalent hours per week (METs h/week). Activity levels were classified into low, moderate, and high categories, as described by the IPAQ scoring protocol (25).

#### Statistical analyses

Quantitative variables were expressed as mean± SD and qualitative variables were shown as numbers and percentages. The association between qualitative variables and PRAL and NEAP quartiles was evaluated with the chi-square test. The relationship between quantitative variables and PRAL and NEAP quartiles was determined by one-way analysis of variance (ANOVA). The dietary intakes of participants were compared using analysis of covariance (ANCOVA), and then were adjusted for the confounding factors, including age, PA, BMI, and energy intake among PRAL and NEAP quartiles. Confounding factors were determined from a best-fit model and those variables with higher Likelihood Ratio Test (LRT) scores were chosen. The Multinomial Logistic Regression (MLR) model was applied to assess the connection between PRAL and NEAP quartiles and headache severity and disability in crude and adjusted models. In this model, as dependent variables, VAS tertiles and MIDAS quartiles were used, and as covariates, quartiles of PRAL and NEAP were applied in MLR model. After that, to evaluate the adjusted odds ratio, confounding

factors were adjusted in MLR model. For determining the association between duration of each headache attack over the last month (Dependent variable) and the quartiles of PRAL and NEAP (Independent variables), linear regression analysis was applied, and then adjusted for confounding factors. To perform statistical analysis, SPSS statistics version 22.0 (IBM Inc., USA) was exploited and p<0.05 was considered as the level of statistical significance.

### Results

#### Study population characteristics

The characteristics of 266 migraine patients were analyzed in this study. The mean (±SD) age, BMI, height, body weight, and physical activity of participants were 34.3 (7.8) years, 26.5 (4.8) kg/m<sup>2</sup>, 161.8 (5.1) cm, 69.4 (13.0) kg, 407.7 (519.1) MET/Min/week, respectively. The percentage of healthy weight (BMI of 18.5-24.9), overweight (BMI 25-29.9) and obesity (BMI ≥30) were 47.8, 29.3 and 22.9, respectively. Based on the selfreport of our participants, 181 individuals (68.04%) of total participants had reported that some dietary items could increase their headache severity. Among them, 152 individuals (83.97%) eliminated these dietary items from their diet. Based on VAS questionnaire, the number (%) of severe, moderate, and mild pain were 114 (42.9), 115 (43.2), and 37 (13.9), respectively. Moreover, according to MIDAS questionnaire, the number (%) of cases with severe, moderate, mild, and without disability were 118 (44.4), 46 (17.3), 66 (24.8) and 36 (13.65), respectively. The mean (Range) duration of each headache attack over the previous month was 10.57 (0.5-72) hours.

# *Quantitative and qualitative variables and PRAL and NEAP quartiles*

The general characteristics of the participants among quartiles of PRAL and NEAP are presented in table 1. Quantitative and qualitative variables across PRAL and NEAP quartiles did not indicate any significant differences among participants. However, mean duration of headache had a statistically significant difference across PRAL and NEAP quartiles (p<0.05), with the ascending trend from the lowest to highest quartiles.

# Diet-dependent acid load and dietary intake

Food and nutrient intake of the study population

among PRAL and NEAP quartiles is provided in table 2. Both diet-dependent acid loads (*i.e.*, PRAL and NEAP) were positively associated with total energy intake, carbohydrate, protein, fat, phosphorus, and sodium (p<0.001), and inversely were associated with potassium, calcium, and magnesium levels (p<0.001). With respect to some food groups, a diet with higher acid load significantly has more refined grain, red meat, and dairy (p<0.001), while a diet with lower acid load has more vegetables and fruits (p<0.001). However, legumes and nuts were not related with PRAL (p=0.23) and NEAP (p=0.99).

# Diet-dependent acid load and migraine headache

The association between severity, disability, and duration of headaches in migraine patients and dietdependent acid load quartiles in crude and adjusted model is shown in table 3. Multinomial logistic regression in the crude model showed that despite lower quartiles, individuals in the highest quartile of PRAL (OR=2.11, 95% CI=1.48-2.99, p<0.001) and NEAP (OR=1.72, 95% CI=1.23-2.40, p=0.001) were more likely to have severe headaches (Based on VAS). In adjusted model, subjects in the highest quartile of RPAL (OR=1.87, 95% CI=1.19-2.96, p=0.007) and NEAP (OR=1.58, 95% CI=1.02-2.44, p=0.03) compared with those in the lowest quartile were more likely to have severe headaches.

However, no statistically significant correlation was found between odds of severe disability (Based on MIDAS) and PRAL (OR=1.34, 95% CI=0.95-1.91, p=0.09) and NEAP score (OR=1.16, 95% CI=0.82-1.64, p=0.39) in crude model, or even after adjusting confounders.

Linear regression analysis in crude model showed a statistically significant direct correlation between duration of each headache attack and quartiles of PRAL ( $\beta$ =0.21, 95% CI=0.99-3.46, p<0.001) and NEAP ( $\beta$ =0.22, 95% CI=1.10-3.56, p<0.001). Even after adjusting for potential confounders, PRAL ( $\beta$ =0.14, 95% CI=0.56–2.94, p=0.04) and NEAP scores ( $\beta$ =0.18, 95% CI=0.45-3.34, p=0.01) indicated a significant positive correlation with headache duration.

## Discussion

To the best of our knowledge, the present study is

### Table 1. General characteristics of study population among quartiles (Q) of PRAL and NEAP

		PRAL			
	Q1	Q2	Q3	Q4	*n valuo
	(n=66)	(n=66)	(n=68)	(n=66)	p-value
PRAL, <i>mEq/day</i>					
Range	<-37.48	-37.48 to -13.2	-13.2 to 2.89	>2.89	
Mean± SD	-67.29±24.2	-25.61±8.04	-4.66±4.92	11.22±8.04	
Quantitative variables					
Age (years)	34.7±7.78	35.42 ±7.78	34.32 ±7.53	32.82 ±8.28	0.276
Height ( <i>cm</i> )	161±5.24	161.88±5.72	161.96±4.73	162.64±4.8	0.337
Weight ( <i>kg</i> )	70.97±12.27	69.1±11.19	71.09±15.07	66.42±12.91	0.132
BMI (kg/m <sup>2</sup> )	27.35±4.46	26.43±4.45	27.11±5.76	25.07±4.47	0.059
PA (MET-h/wk)	454.21±438.6	485.9±472.79	365.27±686.06	326.82±425.09	0.251
Headache duration (hour)	7.75±4.41	9.79±13.47	11.07±11.76	13.23±13.87	0.190
Qualitative variables					
Current smoker					
Yes	3(23.1)	5(38.5)	4(30.8)	1(7.7)	0.423
No	63(24.9)	61(24.1)	64(25.3)	65(25.7)	
Education					
Undergraduate	26(25)	29(27.9)	31(29.8)	18(17.3)	0.143
Bachelor	30(29.4)	23(22.5)	22(21.6)	27(26.5)	
Master	10(16.7)	14(23.3)	15(25)	21(35)	
Marital					
Married	50(26.6)	48(25.5)	47(25)	43(22.9)	0.723
Single	15(20.3)	18(24.3)	20(27)	21(28.4)	
Divorced	1(25)	0(0)	1(25)	2(50)	
		NEAP			
	Q1	Q2	Q3	Q4	***
	Q1 (n=66)	Q2 (n=67)	Q3 (n=67)	Q4 (n=66)	*p-value
NEAP, mEq/day	Q1 (n=66)	Q2 (n=67)	Q3 (n=67)	Q4 (n=66)	*p-value
NEAP, mEq/day Range	Q1 (n=66) <22.87	Q2 (n=67) 22.87 to 35.41	Q3 (n=67) 35.41 to 44.27	Q4 (n=66) >44.27	*p-value
NEAP, mEq/day Range Mean± SD	Q1 (n=66) <22.87 18.07±3.2	Q2 (n=67) 22.87 to 35.41 28.51±3.77	Q3 (n=67) 35.41 to 44.27 39.52±2.65	Q4 (n=66) >44.27 51.13±7.66	*p-value
NEAP, mEq/day Range Mean± SD Quantitative variables	Q1 (n=66) <22.87 18.07±3.2	Q2 (n=67) 22.87 to 35.41 28.51±3.77	Q3 (n=67) 35.41 to 44.27 39.52±2.65	Q4 (n=66) >44.27 51.13±7.66	*p-value
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years)	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58	*p-value 0.093
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> )	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84	*p-value 0.093 0.462
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> )	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22	*p-value 0.093 0.462 0.508
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg/m</i> <sup>2</sup> )	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6	*p-value 0.093 0.462 0.508 0.220
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg</i> /m <sup>2</sup> ) PA (MET- <i>h/wk</i> )	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59 316.26±393.91	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01	*p-value 0.093 0.462 0.508 0.220 0.351
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg/m</i> <sup>2</sup> ) PA (MET- <i>h/wk</i> ) Headache duration (hour)	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59 316.26±393.91 11.2±12.02	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32	*p-value 0.093 0.462 0.508 0.220 0.351 0.010
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg/m</i> <sup>2</sup> ) PA (MET- <i>h/wk</i> ) Headache duration (hour) Qualitative variables	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59 316.26±393.91 11.2±12.02	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32	*p-value 0.093 0.462 0.508 0.220 0.351 0.010
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg/m</i> <sup>2</sup> ) PA (MET- <i>h/wk</i> ) Headache duration (hour) Qualitative variables Current smoker	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59 316.26±393.91 11.2±12.02	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32	*p-value 0.093 0.462 0.508 0.220 0.351 0.010
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg/m</i> <sup>2</sup> ) PA (MET- <i>h/wk</i> ) Headache duration (hour) Qualitative variables Current smoker Yes	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44 4(30.8)	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23 4(30.8)	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59 316.26±393.91 11.2±12.02 4(30.8)	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32	*p-value 0.093 0.462 0.508 0.220 0.351 0.010 0.541
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg/m</i> <sup>2</sup> ) PA (MET- <i>h/wk</i> ) Headache duration (hour) Qualitative variables Current smoker Yes No	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44 4(30.8) 62(24.5)	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23 4(30.8) 63(24.9)	Q3 (n=67) 35.41  to  44.27 $39.52\pm2.65$ $33.34\pm7.01$ $161.99\pm4.86$ $69.58\pm14.54$ $26.53\pm5.59$ $316.26\pm393.91$ $11.2\pm12.02$ 4(30.8) 63(24.9)	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32 1(7.7) 65(25.7)	*p-value 0.093 0.462 0.508 0.220 0.351 0.010 0.541
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg/m</i> <sup>2</sup> ) PA (MET- <i>h/wk</i> ) Headache duration (hour) Qualitative variables Current smoker Yes No	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44 464.97±4.44	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23 4(30.8) 63(24.9)	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59 316.26±393.91 11.2±12.02 4(30.8) 63(24.9)	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32 1(7.7) 65(25.7)	*p-value 0.093 0.462 0.508 0.220 0.351 0.010 0.541
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg/m</i> <sup>2</sup> ) PA (MET- <i>h/wk</i> ) Headache duration (hour) Qualitative variables Current smoker Yes No Education Undergraduate	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44 4(30.8) 62(24.5) 28(26.9)	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23 4(30.8) 63(24.9) 24(23.1)	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59 316.26±393.91 11.2±12.02 4(30.8) 63(24.9) 32(30.8)	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32 1(7.7) 65(25.7) 20(19.2)	*p-value 0.093 0.462 0.508 0.220 0.351 0.010 0.541
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg/m</i> <sup>2</sup> ) PA (MET- <i>h/wk</i> ) Headache duration (hour) Qualitative variables Current smoker Yes No Education Undergraduate Bachelor	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44 4(30.8) 62(24.5) 28(26.9) 28(26.9) 28(27.5)	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23 4(30.8) 63(24.9) 24(23.1) 30(29.4)	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59 316.26±393.91 11.2±12.02 4(30.8) 63(24.9) 32(30.8) 18(28.3)	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32 1(7.7) 65(25.7) 20(19.2) 26(25.5)	*p-value 0.093 0.462 0.508 0.220 0.351 0.010 0.541 0.116
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg/m</i> <sup>2</sup> ) PA (MET- <i>h/wk</i> ) Headache duration (hour) Qualitative variables Current smoker Yes No Education Undergraduate Bachelor	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44 463.8) 62(24.5) 28(26.9) 28(27.5) 10(16.7)	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23 4(30.8) 63(24.9) 24(23.1) 30(29.4) 13(21.7)	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59 316.26±393.91 11.2±12.02 4(30.8) 63(24.9) 32(30.8) 18(28.3) 17(28.3)	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32 1(7.7) 65(25.7) 20(19.2) 26(25.5) 20(33.3)	*p-value 0.093 0.462 0.508 0.220 0.351 0.010 0.541 0.116
NEAP, mEq/dayRangeMean± SDQuantitative variablesAge (years)Height (cm)Weight (kg)BMI (kg/m²)PA (MET-h/wk)Headache duration (hour)Qualitative variablesCurrent smokerYesNoEducationUndergraduateBachelorMasterMarital	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44 464.97±420.69 7.12±4.44 28(26.9) 28(27.5) 10(16.7)	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23 4(30.8) 63(24.9) 24(23.1) 30(29.4) 13(21.7)	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59 316.26±393.91 11.2±12.02 4(30.8) 63(24.9) 32(30.8) 18(28.3) 17(28.3)	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32 1(7.7) 65(25.7) 20(19.2) 26(25.5) 20(33.3)	*p-value 0.093 0.462 0.508 0.220 0.351 0.010 0.541 0.116
NEAP, mEq/day Range Mean± SD Quantitative variables Age (years) Height ( <i>cm</i> ) Weight ( <i>kg</i> ) BMI ( <i>kg/m</i> <sup>2</sup> ) PA (MET- <i>h/wk</i> ) Headache duration (hour) Qualitative variables Current smoker Yes No Education Undergraduate Bachelor Master Marital	Q1 (n=66) <22.87 $18.07\pm3.2$ $34.2\pm8.17$ $161.42\pm5.56$ $70.48\pm12.53$ $27.03\pm4.54$ $464.97\pm420.69$ $7.12\pm4.44$ 464.97±420.69 $7.12\pm4.44$ 28(26.9) 28(26.9) 28(27.5) 10(16.7)	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23 4(30.8) 63(24.9) 24(23.1) 30(29.4) 13(21.7) 51(27.1)	Q3 (n=67) 35.41  to  44.27 $39.52\pm2.65$ $33.34\pm7.01$ $161.99\pm4.86$ $69.58\pm14.54$ $26.53\pm5.59$ $316.26\pm393.91$ $11.2\pm12.02$ 4(30.8) 63(24.9) 32(30.8) 18(28.3) 17(28.3) 17(28.3)	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32 (1(7.7) 65(25.7) 20(19.2) 26(25.5) 20(33.3) 43(22.9)	*p-value 0.093 0.462 0.508 0.220 0.351 0.010 0.541 0.116 0.116
NEAP, mEq/dayRangeMean± SDQuantitative variablesAge (years)Height (cm)Weight (kg)BMI (kg/m²)PA (MET-h/wk)Headache duration (hour)Qualitative variablesCurrent smokerYesNoEducationUndergraduateBachelorMaritalMarriedSingle	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44 4(30.8) 62(24.5) 28(26.9) 28(27.5) 10(16.7) 47(25) 18(24.3)	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23 4(30.8) 63(24.9) 24(23.1) 30(29.4) 13(21.7) 51(27.1) 15(20.3)	Q3 (n=67) 35.41 to 44.27 39.52±2.65 33.34±7.01 161.99±4.86 69.58±14.54 26.53±5.59 316.26±393.91 11.2±12.02 4(30.8) 63(24.9) 32(30.8) 18(28.3) 17(28.3) 17(28.3) 47(25) 20(27)	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32 1(7.7) 65(25.7) 20(19.2) 26(25.5) 20(33.3) 43(22.9) 21(28.4)	*p-value 0.093 0.462 0.508 0.220 0.351 0.010 0.541 0.116 0.116 0.741
NEAP, mEq/dayRangeMean± SDQuantitative variablesAge (years)Height (cm)Weight (kg)BMI (kg/m²)PA (MET-h/wk)Headache duration (hour)Qualitative variablesCurrent smokerYesNoEducationUndergraduateBachelorMaritalMarriedSingleDivorced	Q1 (n=66) <22.87 18.07±3.2 34.2±8.17 161.42±5.56 70.48±12.53 27.03±4.54 464.97±420.69 7.12±4.44 464.97±420.69 7.12±4.44 28(26.9) 28(26.9) 28(27.5) 10(16.7) 47(25) 18(24.3) 1(25)	Q2 (n=67) 22.87 to 35.41 28.51±3.77 36.43±7.34 161.39±5.26 70.22±11.68 27.02±4.63 437.92±447.82 9.26±12.23 4(30.8) 63(24.9) 24(23.1) 30(29.4) 13(21.7) 51(27.1) 15(20.3) 1(25)	Q3 (n=67) 35.41  to  44.27 $39.52\pm2.65$ $33.34\pm7.01$ $161.99\pm4.86$ $69.58\pm14.54$ $26.53\pm5.59$ $316.26\pm393.91$ $11.2\pm12.02$ 4(30.8) 63(24.9) 32(30.8) 18(28.3) 17(28.3) 17(25) 20(27) 0(0)	Q4 (n=66) >44.27 51.13±7.66 33.27±8.58 162.68±4.84 67.34±13.22 25.4±4.6 412.70±740.01 14.28±14.32 1(7.7) 65(25.7) 20(19.2) 26(25.5) 20(33.3) 43(22.9) 21(28.4) 2(50)	*p-value 0.093 0.462 0.508 0.220 0.351 0.010 0.541 0.116 0.116 0.741

BMI, body mass index; NEAP, net endogenous acid production; PA, physical activity; PRAL, potential renal acid load.

Quantitative variables (age, height, weight, BMI, PA, Headache duration) reported as Mean± SD.

Qualitative variables (current smoker, education and marital) reported as number (%).

\* Chi-square test and ANOVA were applied for qualitative and quantitative variables, respectively.

Tahle 2	Dietary	intake of s	tudv n	onulation	among	quartiles	(O)	of PRAI	and NEAP
Table 2.	Dielaiy	IIIIane UI S	iuuy p	opulation	annong	yuai ilies	(9)	ULLUL	and NEAF

		PRAL			
	Q1 (n=66)	Q2 (n=66)	Q3 (n=68)	Q4 (n=66)	*p-value
Nutrient intake					
Energy <sup>a</sup> ( <i>kcal/d</i> )	1875.84±403.78	2026.13±436.91	2504.86±516.53	2524.53±363.35	<0.001ª
Carbohydrate (g/d)	268.83±67.02	265.84±56.5	313.78±71.09	322.78±58.43	<0.001
Protein (g/d)	77.09±19.63	73.49±14.68	80.42±13.58	86.4±12.48	<0.001
Fat ( <i>g/d</i> )	64.79±13.76	80.6±29.6	108.29±31.1	103.33±23.93	<0.001
Phosphorus (mg/d)	1404.17±350.11	1306.74±270.61	1430.1±303.5	1435.22±299.24	<0.001
Potassium ( <i>mg/d</i> )	5730.28±1505.7	3957.6±680.78	3466.4±627.94	3036.76±616.37	<0.001
Calcium ( <i>mg/d</i> )	1820.3±495.14	1232.86±270.52	1082.84±273.47	928.57±235.98	<0.001
Magnesium ( <i>mg/d</i> )	471.71±144.19	385.22±90.1	380.2±112.57	361.22±76.86	<0.001
Sodium ( <i>mg/d</i> )	3478.52±588.39	3575.02±649.66	3964.42±841.33	3973.89±926.74	<0.001
Food intake					
Vegetables (g/d)	375.76±103.21	256.7±82.2	175.93±77.9	146.51±76.32	<0.001
Fruits (g/d)	289.73±199	198.04±159.49	131.76±87.99	120.14±71.2	<0.001
Dairy (g/d)	258.1±73.35	248.94±104.05	303.54±105.97	303.11±112.99	<0.001
Legumes and nut (g/d)	70.53±43.05	49.79±41.6	55.95±39.32	63.65±50.52	0.231
Refined grain (g/d)	187.91±73.99	288.43±123.45	380.72±173.34	410.09±145.82	<0.001
Red meat $(a/d)$	7.95±5.86	22.12±30.03	17.55±14.93	22.63±13.21	<0.001
(3 * )					
		NEAP			
	Q1 (n=66)	NEAP Q2 (n=67)	Q3 (n=67)	Q4 (n=66)	*p-value
Nutrient intake	Q1 (n=66)	NEAP Q2 (n=67)	Q3 (n=67)	Q4 (n=66)	*p-value
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> )	Q1 (n=66) 1804.8±367.35	NEAP Q2 (n=67) 2156.32±440.39	Q3 (n=67) 2417.73±560.11	Q4 (n=66) 2543.49±354.21	*p-value <0.001ª
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07	NEAP Q2 (n=67) 2156.32±440.39 286.79±65.18	Q3 (n=67) 2417.73±560.11 306.7±74.61	Q4 (n=66) 2543.49±354.21 318.15±59.08	*p-value <0.001ª <0.001
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07	NEAP Q2 (n=67) 2156.32±440.39 286.79±65.18 75.61±17.65	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33	Q4 (n=66) 2543.49±354.21 318.15±59.08 85.23±13.52	*p-value <0.001ª <0.001 <0.001
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> ) Fat ( <i>g/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83	NEAP Q2 (n=67) 2156.32±440.39 286.79±65.18 75.61±17.65 85.15±27.04	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33 100.83±33.72	Q4 (n=66) 2543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64	*p-value <0.001ª <0.001 <0.001 <0.001
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> ) Fat ( <i>g/d</i> ) Phosphorus ( <i>mg/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83 1333.59±305.3	NEAP           Q2 (n=67)           2156.32±440.39           286.79±65.18           75.61±17.65           85.15±27.04           1374.85±341.62	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33 100.83±33.72 1463.51±262.33	Q4 (n=66) 2543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64 1400.58±316.41	*p-value <0.001ª <0.001 <0.001 <0.001 <0.001
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> ) Fat ( <i>g/d</i> ) Phosphorus ( <i>mg/d</i> ) Potassium ( <i>mg/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83 1333.59±305.3 5526.39±1550.3	NEAP           Q2 (n=67)           2156.32±440.39           286.79±65.18           75.61±17.65           85.15±27.04           1374.85±341.62           4111.62±1044.1	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33 100.83±33.72 1463.51±262.33 3594.27±511.71	Q4 (n=66) 2543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64 1400.58±316.41 2969.99±633.53	*p-value <0.001ª <0.001 <0.001 <0.001 <0.001 <0.001
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> ) Fat ( <i>g/d</i> ) Phosphorus ( <i>mg/d</i> ) Potassium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83 1333.59±305.3 1333.59±305.3 5526.39±1550.3	NEAP           Q2 (n=67)           2156.32±440.39           286.79±65.18           75.61±17.65           85.15±27.04           1374.85±341.62           4111.62±1044.1           1254.7±352.29	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33 100.83±33.72 1463.51±262.33 3594.27±511.71 1139.2±266.3	Q4 (n=66) 2543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64 1400.58±316.41 2969.99±633.53 926.53±248.21	*p-value <0.001ª <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Nutrient intakeEnergyª (kcal/d)Carbohydrate (g/d)Protein (g/d)Fat (g/d)Phosphorus (mg/d)Potassium (mg/d)Calcium (mg/d)Magnesium (mg/d)	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83 1333.59±305.3 1333.59±305.3 5526.39±1550.3 1750.77±533.72 447.12±138.68	NEAP           Q2 (n=67)           2156.32±440.39           286.79±65.18           75.61±17.65           85.15±27.04           1374.85±341.62           4111.62±1044.1           1254.7±352.29           408.84±117.39	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33 100.83±33.72 1463.51±262.33 3594.27±511.71 1139.2±266.3 392.38±103.89	Q4 (n=66) 25543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64 1400.58±316.41 2969.99±633.53 926.53±248.21 349.36±76.68	*p-value <0.001° <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> ) Fat ( <i>g/d</i> ) Phosphorus ( <i>mg/d</i> ) Potassium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> ) Sodium ( <i>mg/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83 1333.59±305.3 5526.39±1550.3 1750.77±533.72 447.12±138.68 3340.07±556.32	NEAP           Q2 (n=67)           2156.32±440.39           286.79±65.18           75.61±17.65           85.15±27.04           1374.85±341.62           4111.62±1044.1           1254.7±352.29           408.84±117.39           3506.44±604.41	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33 100.83±33.72 1463.51±262.33 3594.27±511.71 1139.2±266.3 392.38±103.89 4085±739.17	Q4 (n=66) 25543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64 1400.58±316.41 2969.99±633.53 926.53±248.21 349.36±76.68 4048.89±942.62	*p-value <0.001* <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> ) Fat ( <i>g/d</i> ) Phosphorus ( <i>mg/d</i> ) Potassium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> ) Magnesium ( <i>mg/d</i> ) Sodium ( <i>mg/d</i> ) Food intake	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83 1333.59±305.3 1333.59±305.3 5526.39±1550.3 1750.77±533.72 447.12±138.68 3340.07±556.32	NEAP           Q2 (n=67)           2156.32±440.39           286.79±65.18           75.61±17.65           85.15±27.04           1374.85±341.62           4111.62±1044.1           1254.7±352.29           408.84±117.39           3506.44±604.41	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33 100.83±33.72 1463.51±262.33 3594.27±511.71 1139.2±266.3 392.38±103.89 4085±739.17	Q4 (n=66) 25543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64 1400.58±316.41 2969.99±633.53 926.53±248.21 349.36±76.68 4048.89±942.62	*p-value <0.001ª <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> ) Fat ( <i>g/d</i> ) Phosphorus ( <i>mg/d</i> ) Potassium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> ) Magnesium ( <i>mg/d</i> ) Sodium ( <i>mg/d</i> ) Food intake Vegetables ( <i>g/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83 1333.59±305.3 5526.39±1550.3 5526.39±1550.3 1750.77±533.72 447.12±138.68 3340.07±556.32	NEAP           Q2 (n=67)           2156.32±440.39           286.79±65.18           75.61±17.65           85.15±27.04           1374.85±341.62           4111.62±1044.1           1254.7±352.29           408.84±117.39           3506.44±604.41           261.98±83.96	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33 100.83±33.72 1463.51±262.33 3594.27±511.71 1139.2±266.3 392.38±103.89 4085±739.17	Q4 (n=66) 25543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64 1400.58±316.41 2969.99±633.53 926.53±248.21 349.36±76.68 4048.89±942.62	*p-value <0.001° <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> ) Fat ( <i>g/d</i> ) Phosphorus ( <i>mg/d</i> ) Potassium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> ) Sodium ( <i>mg/d</i> ) Food intake Vegetables ( <i>g/d</i> ) Fruits ( <i>g/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83 1333.59±305.3 1333.59±305.3 5526.39±1550.3 1750.77±533.72 447.12±138.68 3340.07±556.32 3377.19±102.26	NEAP           Q2 (n=67)           2156.32±440.39           286.79±65.18           75.61±17.65           85.15±27.04           1374.85±341.62           4111.62±1044.1           1254.7±352.29           408.84±117.39           3506.44±604.41           261.98±83.96           206±164.65	Q3 (n=67) 2417.73±560.11 306.7±74.61 305.7±74.61 100.83±33.72 1463.51±262.33 3594.27±511.71 3594.27±511.71 1139.2±266.3 392.38±103.89 4085±739.17 185.29±68.39 128.19±76.53	Q4 (n=66) 25543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64 1400.58±316.41 2969.99±633.53 926.53±248.21 349.36±76.68 4048.89±942.62 131.99±69.82 114.28±74.6	*p-value (
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> ) Fat ( <i>g/d</i> ) Phosphorus ( <i>mg/d</i> ) Potassium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> ) Sodium ( <i>mg/d</i> ) Food intake Vegetables ( <i>g/d</i> ) Fruits ( <i>g/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83 1333.59±305.3 1333.59±305.3 5526.39±1550.3 5526.39±1550.3 1750.77±533.72 447.12±138.68 3340.07±556.32 3377.19±102.26 290.64±192.99 256.24±68.49	NEAP           Q2 (n=67)           2156.32±440.39           286.79±65.18           75.61±17.65           85.15±27.04           1374.85±341.62           4111.62±1044.1           1254.7±352.29           408.84±117.39           3506.44±604.41           261.98±83.96           206±164.65           257.76±119.64	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33 100.83±33.72 1463.51±262.33 3594.27±511.71 1139.2±266.3 392.38±103.89 4085±739.17 185.29±68.39 128.19±76.53 295.88±90.66	Q4 (n=66) 25543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64 1400.58±316.41 2969.99±633.53 926.53±248.21 349.36±76.68 4048.89±942.62 131.99±69.82 114.28±74.6 303.95±116.04	*p-value <0.001° <0.001° <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> ) Fat ( <i>g/d</i> ) Phosphorus ( <i>mg/d</i> ) Potassium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> ) Sodium ( <i>mg/d</i> ) Sodium ( <i>mg/d</i> ) Frood intake Vegetables ( <i>g/d</i> ) Fruits ( <i>g/d</i> ) Legumes and nut ( <i>g/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83 1333.59±305.3 5526.39±1550.3 5526.39±1550.3 1750.77±533.72 447.12±138.68 3340.07±556.32 3340.07±556.32 3377.19±102.26 290.64±192.99 256.24±68.49 61.57±37.27	NEAP           Q2 (n=67)           2156.32±440.39           286.79±65.18           75.61±17.65           85.15±27.04           1374.85±341.62           4111.62±1044.1           1254.7±352.29           408.84±117.39           3506.44±604.41           261.98±83.96           206±164.65           257.76±119.64           61.55±47.32	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33 100.83±33.72 1463.51±262.33 3594.27±511.71 1139.2±266.3 392.38±103.89 4085±739.17 185.29±68.39 128.19±76.53 295.88±90.66 57.87±48.35	Q4 (n=66) 25543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64 1400.58±316.41 2969.99±633.53 926.53±248.21 349.36±76.68 4048.89±942.62 131.99±69.82 114.28±74.6 303.95±116.04 58.36±43.73	*p-value (
Nutrient intake Energy <sup>a</sup> ( <i>kcal/d</i> ) Carbohydrate ( <i>g/d</i> ) Protein ( <i>g/d</i> ) Fat ( <i>g/d</i> ) Phosphorus ( <i>mg/d</i> ) Potassium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> ) Calcium ( <i>mg/d</i> ) Sodium ( <i>mg/d</i> ) Sodium ( <i>mg/d</i> ) Food intake Vegetables ( <i>g/d</i> ) Fruits ( <i>g/d</i> ) Dairy ( <i>g/d</i> ) Legumes and nut ( <i>g/d</i> ) Refined grain ( <i>g/d</i> )	Q1 (n=66) 1804.8±367.35 258.48±59.07 73.04±18.07 62.95±13.83 1333.59±305.3 5526.39±1550.3 5526.39±1550.3 1750.77±533.72 447.12±138.68 3340.07±556.32 3340.07±556.32 290.64±192.99 256.24±68.49 61.57±37.27 181.11±70.18	NEAP           Q2 (n=67)           2156.32±440.39           286.79±65.18           75.61±17.65           85.15±27.04           1374.85±341.62           4111.62±1044.1           1254.7±352.29           408.84±117.39           3506.44±604.41           261.98±83.96           206±164.65           257.76±119.64           61.55±47.32           303.47±139.47	Q3 (n=67) 2417.73±560.11 306.7±74.61 83.29±10.33 100.83±33.72 1463.51±262.33 3594.27±511.71 1139.2±266.3 392.38±103.89 4085±739.17 128.19±76.53 295.88±90.66 57.87±48.35	Q4 (n=66) 25543.49±354.21 318.15±59.08 85.23±13.52 107.7±24.64 1400.58±316.41 2969.99±633.53 926.53±248.21 349.36±76.68 4048.89±942.62 131.99±69.82 114.28±74.6 303.95±116.04 58.36±43.73 419.46±141.44	*p-value <0.001° <0.001° <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001

\* Based on ANCOVA, adjusted for confounders.

<sup>a</sup> Adjusted for confounders except total energy.

Mean ± SD (all such values).

PRAL						
	Crud	le models		Adju	sted models	
	OR	(0.95% CI)	p-value	OR	(0.95% CI)	p-value
VAS						
Mild pain <sup>∞</sup>	-	-	-	-	-	-
Moderate pain	1.53	(1.08-2.16)	0.010	1.25	(0.81-1.93)	0.311
Sever pain	2.11	(1.48-2.99)	<0.001	1.87	(1.19-2.96)	0.007
MIDAS						
Without disability <sup>∞</sup>	-	-	-	-	-	-
Mild disability	1.17	(0.80-1.70)	0.407	1.15	(0.72-1.85)	0.542
Moderate disability	1.30	(0.86-1.95)	0.201	1.42	(0.84-2.42)	0.182
Severe disability	1.34	(0.95-1.91)	0.097	1.44	(0.89-2.33)	0.137
Each attack mean duration	*0.21	(0.99-3.46)	<0.001	*0.14	(0.56-2.94)	0.041
NEAP						
NEAP	Crı	ide models	n-valuo	Adju	sted models	n-valuo
NEAP	Crı OR	ıde models (0.95% CI)	p-value	Adju OR	sted models (0.95% Cl)	p-value
VAS	Crı OR	ide models (0.95% Cl)	p-value	Adju OR	sted models (0.95% Cl)	p-value
NEAP VAS Mild pain <sup>∞</sup>	Crı OR -	ıde models (0.95% CI)	p-value	Adju OR	sted models (0.95% Cl)	p-value
NEAP VAS Mild pain <sup>∞</sup> Moderate pain	Crı OR - 1.36	ide models (0.95% CI) - (0.97-1.90)	p-value - 0.061	Adju OR - 1.09	sted models (0.95% CI) - (0.72-1.64)	p-value - 0.671
NEAP VAS Mild pain <sup>∞</sup> Moderate pain Sever pain	Cru OR - 1.36 1.72		p-value - 0.061 0.001	Adju OR - 1.09 1.58	sted models (0.95% CI) - (0.72-1.64) (1.02-2.44)	p-value - 0.671 0.036
NEAP VAS Mild pain <sup>∞</sup> Moderate pain Sever pain MIDAS	Сги ОК - 1.36 1.72	ide models (0.95% CI) - (0.97-1.90) (1.23 -2.40)	p-value - 0.061 0.001	Adju OR - 1.09 1.58	sted models (0.95% CI) - (0.72-1.64) (1.02-2.44)	p-value - 0.671 0.036
NEAP VAS Mild pain <sup>®</sup> Moderate pain Sever pain MIDAS Without disability <sup>®</sup>	Сгц ОК - 1.36 1.72	ide models (0.95% CI) - (0.97-1.90) (1.23 -2.40)	p-value - 0.061 0.001	Adju OR - 1.09 1.58	sted models (0.95% CI) - (0.72-1.64) (1.02-2.44) -	p-value - 0.671 0.036
NEAP VAS Mild pain <sup>®</sup> Moderate pain Sever pain MIDAS Without disability <sup>®</sup> Mild disability	Сги ОК - 1.36 1.72 - 1.19	ide models (0.95% CI) - (0.97-1.90) (1.23 -2.40) - (0.82-1.73)	p-value - 0.061 0.001 - 0.343	Adju OR - 1.09 1.58 - 1.23	sted models (0.95% CI) - (0.72-1.64) (1.02-2.44) - (0.77-1.95)	p-value - 0.671 0.036 - 0.371
NEAP VAS Mild pain <sup>®</sup> Moderate pain Sever pain MIDAS Without disability <sup>®</sup> Mild disability Moderate disability	Сгц ОК - 1.36 1.72 - 1.19 1.19	ide models (0.95% CI) - (0.97-1.90) (1.23 -2.40) - (0.82-1.73) (0.79-1.79)	<b>p-value</b> - 0.061 0.001 - 0.343 0.384	Adju OR - 1.09 1.58 - 1.23 1.41	sted models (0.95% CI) - (0.72-1.64) (1.02-2.44) - (0.77-1.95) (0.84-2.38)	p-value - 0.671 0.036 - 0.371 0.184
NEAP VAS Mild pain <sup>®</sup> Moderate pain Sever pain MIDAS Without disability <sup>®</sup> Mild disability Moderate disability Severe disability	Сги ОК - 1.36 1.72 - 1.19 1.19 1.16	ide models (0.95% CI) - (0.97-1.90) (1.23 -2.40) (0.82-1.73) (0.79-1.79) (0.82-1.64)	p-value - 0.061 0.001 - 0.343 0.384 0.391	Adju OR - 1.09 1.58 - 1.23 1.41 1.34	sted models (0.95% CI) - (0.72-1.64) (1.02-2.44) - (0.77-1.95) (0.84-2.38) (0.84-2.15)	<b>p-value</b> - 0.671 0.036 - 0.371 0.184 0.212

MIDAS, Migraine Disability Assessment Questionnaire; NEAP, net endogenous acid production; PRAL, potential renal acid load; VAS, Visual analog scale.

\* The  $\beta$  coefficient has been shown.

 $\infty$  Considered as reference group.

the first to examine the relationship between the acid load of the habitual diet of adult individuals with duration and intensity of migraine headaches. The main analyses showed that higher dietary acid load is associated with higher headache intensity and duration among migraine patients. To be more specific, dietary acid load, expressed as PRAL and NEAP, was related with higher VAS scores and headache duration. Nevertheless, there was no significant relation between MIDAS scores and any measurements of the dietdependent acid load.

There are possible mechanisms through which the hypothesis of the effect of metabolic acidosis on migraine is formed. Migraine is believed to be a neurovascular disorder induced through a set of actions starting within the brain and then spreading to the blood vessels (26). Thus, changes in brain excitability could be the main trigger of the disease. Acid-Sensing Ion Channels (ASICs) are a family of ion channels, expressed throughout the nervous system and are sensitive to different ranges of pH (27) and ASIC1 is the most prominent and the most highly expressed of all the ASICs which is activated in acidic condition (28). ASIC1 has been speculated to contribute to epilepsy (29). Several studies have also revealed that ASICs within CNS sites can come up with pain signaling. It has also been shown that blockade of these channels is related to attenuated pain behaviors in rats (30).

Several studies suggest a positive association between hypertension and migraine (17,31,32). In a study by Barton and Sibai, it was demonstrated that neurologic signs and symptoms such as persistent headaches are common in women with pre-eclampsia and eclampsia (33). Malignant hypertension, through imposing pressure on cranium, could cause severe headaches. In addition, it was shown in a study by Mirzababaei et al that adherence to the DASH diet, which is the main approach to control blood pressure, is connected with lower headache severity and duration in migraine patients (34). Several studies have also found a link between dietary acid load and hypertension (35,36). It appears that a high dietary acid load may lead to an increased renal excretion which gradually induces negative effect on the renal function that could ultimately raise blood pressure (37,38). Increased calcium excretion is another outcome of high acid load that might culminate in high blood pressure (39,40). Nevertheless, it should be noted that the current data regarding the association of hypertension and migraine is inconclusive as several studies failed to support an association between the two (41). As it was stated by Secil et al, since both migraine and hypertension are prevalent in general population, the fact that a person is suffering from both diseases could be merely due to coincidence (42).

Studies have shown that migraineurs have low levels of brain magnesium during migraine attacks and may also have a magnesium deficiency (43,44). Furthermore, it was demonstrated that menstrual migraine could be due to magnesium deficiency (45). Two clinical trial studies have revealed that oral magnesium supplementation could have a major role in attenuating headaches (46,47). One study did not show any significant difference, but this result has been attributed to the use of a poorly absorbed magnesium salt (48). Under acidic conditions, the human buffer system tries to compensate for acidosis by excreting some elements such as magnesium and calcium. In an animal study, it was confirmed that systemic acid-base balance regulates the expression of proteins that have a role in reabsorbing magnesium (49). The similar results have been achieved by Rylander et al in a study conducted on adult population (50).

According to numerous studies, it appears that stress could be a prominent contributor to migraine. Since cortisol is consistently produced and secreted by the adrenal gland in response to stress, it is believed that this hormone may be involved in the pathogenesis of migraine. As it was shown in a clinical trial study by Peres *et al*, cortisol concentration was significantly high in migraine patients in comparison with the control group (51). There is much evidence that confirms chronic metabolic acidosis is associated with increased glucocorticoid production. Maurer *et al* have shown that the urinary level of cortisol was higher in the people having a sodium- and potassium chloride- rich regimen compared to the one with potassium bicarbonate (52). Also, in a study conducted on healthy children, it was revealed that even moderate elevations in diet-dependent acid loads will influence cortisol secretion (53). However, the role of stress as a trigger of migraine has been questioned recently as several studies have found no relation between the two (54,55), and some others contrarily reported that migraine headaches give rise to stress hormones as the level of cortisol was significantly higher in the control groups only after the onset of attacks (56).

There are certain limitations in our study which are worth considering. The main one might be the number of enlisted subjects that was relatively low. The cross-sectional design of the study is another important limitation as it prevented us from drawing causal inferences. In some epidemiological studies of migraine, significant sex and age differences have been shown (57,58) while in this study, only premenopausal women were recruited. It seems that better insight could be obtained by investigating the variable of sex if men were recruited as the subjects. One of the inevitable limitations of this type of study is that questionnaire responses are subjectively based on participants' memory and their perception of pain.

# Conclusion

While it was found that a diet with higher acid load was statistically associated with a higher risk of migraine headaches, the diet acid load seems not to be a major trigger for migraines due to multiple comparisons, the small effect size, and many environmental and genetics confounders. Therefore, further prospective studies are necessary to confirm these initial findings in order to support the relationship between dietdependent acid load and migraine.

### Acknowledgements

The authors thank the participants and the staff at neurology clinics of Sina and Khatam Alanbia hospitals. This study was confirmed by Tehran University of Medical Sciences (Grants ID: 95-01-103-31348) and the study protocol was confirmed (Ethics code: IR.TUMS. REC.1394.2141) by the Research Committee of the School of Nutritional Sciences and Dietetics of Tehran University of Medical Sciences (TUMS).

# **Conflict of Interest**

The authors report no conflict of interest.

# References

1 .Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey. Eur J Epidemiol 2005;20(3):243-9.

2 .Lanteri-Minet M. Economic burden and costs of chronic migraine. Curr Pain Headache Rep 2014;18(1):385.

3 .Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 2018;19(1):17.

4 .Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine? Brain Behav 2018;8(6):e00950.

5 .Pardutz A, Schoenen J. NSAIDs in the acute treatment of migraine: A review of clinical and experimental data. Pharmaceuticals (Basel) 2010;3(6):1966-87.

6 .Frassetto LA, Todd KM, Morris RC, Jr., Sebastian A. Estimation of net endogenous noncarbonic acid production in humans from diet potassium and protein contents. Am J Clin Nutr 1998;68(3):576-83.

7 .Remer T. Influence of nutrition on acid-base balance--metabolic aspects. Eur J Nutr 2001;40(5):214-20.

8 .Remer T, Dimitriou T, Manz F. Dietary potential renal acid load and renal net acid excretion in healthy, free-living children and adolescents. Am J Clin Nutr 2003;77(5):1255-60.

9 .Akter S, Nanri A, Mizoue T, Noda M, Sawada N, Sasazuki S, et al. Dietary acid load and mortality among Japanese men and women: the Japan Public Health Center–based Prospective Study. Am J Clin Nutr 2017;106(1):146-54.

10 .Saraf-Bank S, Tehrani H, Haghighatdoost F, Moosavian SP, Azadbakht L. The acidity of early pregnancy diet and risk of gestational diabetes mellitus. Clin Nutr 2018;37(6 Pt A):2054-59.

11 .Engberink MF, Bakker SJ, Brink EJ, van Baak MA, van Rooij FJA, Hofman A, et al. Dietary acid load and risk of hypertension: the Rotterdam Study. Am J Clin Nutr 2012;95(6):1438-44.

12 .Roughead ZK, Hunt JR, Johnson LK, Badger TM, Lykken GI. Controlled substitution of soy protein for meat protein: effects on calcium retention, bone, and cardiovascular health indices in postmenopausal women. J Clin Endocrinol Metab 2005;90(1):181-9.

13 .Cao JJ, Johnson LK, Hunt JR. A diet high in meat protein and potential renal acid load increases fractional calcium absorption and urinary calcium excretion without affecting markers of bone resorption or formation in postmenopausal women. J Nutr 2011;141(3):391-7.

14 .Hunt JR, Johnson LK, Fariba Roughead ZK. Dietary protein and calcium interact to influence calcium retention: a controlled feeding study. Am J Clin Nutr 2009;89(5):1357-65.

15 .Frassetto L, Morris RC, Jr., Sellmeyer DE, Todd K, Sebastian A. Diet, evolution and aging--the pathophysiologic effects of the post-agricultural inversion of the potassium-to-sodium and base-to-chloride ratios in the human diet. Eur J Nutr 2001;40(5):200-13.

16 .Bunner AE, Agarwal U, Gonzales JF, Valente F, Barnard ND. Nutrition intervention for migraine: a randomized crossover trial. J Headache Pain 2014;15(1):69.

17 .Cirillo M, Stellato D, Lombardi C, De Santo NG, Covelli V. Headache and cardiovascular risk factors: positive association with hypertension. Headache 1999;39(6):409-16.

18 .Mirmiran P, Hosseini-Esfahanil F, Jessri M, Mahan LK, Shiva N, Azizis F. Does dietary intake by Tehranian adults align with the 2005 dietary guidelines for Americans? Observations from the Tehran lipid and glucose study. J Health

IRANIAN MEDICAL COUNCIL

Popul Nutr 2011;29(1):39-52.

19 .Remer T, Manz F. Estimation of the renal net acid excretion by adults consuming diets containing variable amounts of protein. Am J Clin Nutr 1994;59(6):1356-61.

20 .Frassetto LA, Todd KM, Morris Jr RC, Sebastian A. Estimation of net endogenous noncarbonic acid production in humans from diet potassium and protein contents. Am J Clin Nutr 1998;68(3):576-83.

21 .Levin M. The international classification of headache disorders, (ICHD III)–changes and challenges. Headache: The Journal of Head and Face Pain 2013;53:1383-95.

22 .Ghorbani A, Chitsaz A. Comparison of validity and reliability of the Migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population. Iran J Neurol 2011;10(3-4):39-42.

23 .Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001;56(6 Suppl 1):S20-8.

24 .Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983;17(1):45-56.

25 .Wanner M, Probst-Hensch N, Kriemler S, Meier F, Autenrieth C, Martin BW. Validation of the long international physical activity questionnaire: Influence of age and language region. Prev Med Rep 2016;3:250-6.

26 .Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: A systematic review. Headache 2019;59(3):306-38.

27 .Dussor G. ASICs as therapeutic targets for migraine. Neuropharmacology 2015;94:64-71.

28 .Grunder S, Chen X. Structure, function, and pharmacology of acid-sensing ion channels (ASICs): focus on ASIC1a. Int J Physiol Pathophysiol Pharmacol 2010;2(2):73-94.

29 .Wemmie JA, Taugher RJ, Kreple CJ. Acid-sensing ion channels in pain and disease. Nat Rev Neurosci 2013;14(7):461-71.

30 .Duan B, Wu LJ, Yu YQ, Ding Y, Jing L, Xu L, et al. Upregulation of acid-sensing ion channel ASIC1a in spinal dorsal horn neurons contributes to inflammatory pain hypersensitivity. J Neurosci 2007;27(41):11139-48.

31 .Gudmundsson LS, Thorgeirsson G, Sigfusson N, Sigvaldason H, Johannsson M. Migraine patients have lower systolic but higher diastolic blood pressure compared with controls in a population-based study of 21,537 subjects. The Reykjavik Study. Cephalalgia 2006;26(4):436-44.

32 .Franceschi M, Colombo B, Rossi P, Canal N. Headache in a population-based elderly cohort. An ancillary study to the Italian Longitudinal Study of Aging (ILSA). Headache 1997;37(2):79-82.

33 .Barton JR, Sibai BM. Cerebral pathology in eclampsia. Clin Perinatol 1991 Dec;18(4):891-910.

34 .Mirzababaei A, Khorsha F, Togha M, Yekaninejad MS, Okhovat AA, Mirzaei K. Associations between adherence to dietary approaches to stop hypertension (DASH) diet and migraine headache severity and duration among women. Nutr Neurosci 2020 May;23(5):335-342.

35 .Murakami K, Sasaki S, Takahashi Y, Uenishi K, Japan Dietetic Students' Study for Nutrition and Biomarkers Group. Association between dietary acid-base load and cardiometabolic risk factors in young Japanese women. Br J Nutr 2008;100(3):642-51.

36 .Zhang L, Curhan GC, Forman JP. Diet-dependent net acid load and risk of incident hypertension in United States women. Hypertension 2009;54(4):751-5.

37 .Tanner GA. Renal regulation of acid-base balance: ammonia excretion. Physiologist 1984;27:95-7.

38 .Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985;76(2):667-75.

39 .Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB. Unravelling the links between calcium excretion, salt

intake, hypertension, kidney stones and bone metabolism. J Nephrol 2000;13(3):169-77.

40 .Taylor EN, Mount DB, Forman JP, Curhan GC. Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate, and other factors. Am J Kidney Dis 2006;47(5):780-9.

41 .Hale WE, May FE, Marks RG, Moore MT, Stewart RB. Headache in the elderly: an evaluation of risk factors. Headache 1987;27(5):272-6.

42 .Secil Y, Unde C, Beckmann YY, Bozkaya YT, Ozerkan F, Basoglu M. Blood pressure changes in migraine patients before, during and after migraine attacks. Pain Pract 2010;10(3):222-7.

43 .Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clinical Neurosci 1998;5(1):24-7.

44 .Ramadan NM, Halvorson H, Vande-Linde A, Levine SR, Helpern JA, Welch KM. Low brain magnesium in migraine. Headache 1989;29(7):416-9.

45 .Mauskop A, Altura BT, Altura BM. Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. Headache 2002;42(4):242-8.

46 .Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991;31(5):298-301.

47 .Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16(4):257-63.

48 .Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, et al. Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study. Cephalalgia 1996;16(6):436-40.

49 .Nijenhuis T, Renkema KY, Hoenderop JG, Bindels RJ. Acid-base status determines the renal expression of Ca2+ and Mg2+ transport proteins. J Am Soc Nephrol 2006;17(3):617-26.

50 .Rylander R, Remer T, Berkemeyer S, Vormann J. Acid-base status affects renal magnesium losses in healthy, elderly persons. J Nutr 2006;136(9):2374-7.

51 .Peres MF, Sanchez del Rio M, Seabra ML, Tufik S, Abucham J, Cipolla-Neto J, et al. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 2001;71(6):747-51.

52 .Maurer M, Riesen W, Muser J, Hulter HN, Krapf R. Neutralization of Western diet inhibits bone resorption independently of K intake and reduces cortisol secretion in humans. Am J Physiol Renal Physiol 2003 Jan;284(1):F32-40.

53 .Esche J, Shi L, Sanchez-Guijo A, Hartmann MF, Wudy SA, Remer T. Higher diet-dependent renal acid load associates with higher glucocorticoid secretion and potentially bioactive free glucocorticoids in healthy children. Kidney Int 2016;90(2):325-333.

54 .Patacchioli FR, Monnazzi P, Simeoni S De Filippis S, Salvatori E, Coloprisco G, et al. Salivary cortisol, dehydroepiandrosterone-sulphate (DHEA-S) and testosterone in women with chronic migraine. J Headache Pain 2006;7(2):90-4.

55 .Oncel C, Oflazoglu B, Forta H, Yucel N, Eren N. Plasma cortisol levels in migraineurs between attacks. Agri 2007;19(2):46-8.

56 .Juhasz G, Zsombok T, Gonda X, Nagyne N, Modosne E, Bagdy G. Effects of autogenic training on nitroglycerininduced headaches. Headache 2007;47(3):371-83.

57 .Sinch I, Singh D. Progesterone in the treatment of migraine. Lancet 1947;1(6457):745-7.

58 .Peterlin BL, Gupta S, Ward TN, Macgregor A. Sex matters: evaluating sex and gender in migraine and headache research. Headache 2011;51(6):839-42.